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Thro~bospondin-l (TSP-l), a 450-kDa glycoprotein 
secreted by platelets and endothelial cells at sites of 
tissue injury or inflammation, plays an i~nportant role 
in angiogenesis, inflammation, aqd vascl-llar occlu-
sive skin diseases. Malty of the physiologic altd patho-
logic activities of TSP-l are dependent upon its 
interactiolts with eltdothelial cells. To better ultder-
stand the basis of these activities, we examined the 
mechanisms mediating the binding of human dermal 
microvascular endothelial cells (HDMEC) to hnmo-
bilized TSp-1. HDMEC bound to but did not spread 
on TSP-l in a concentration-dependent Inanner. 
M onoclonal antibodies (MoAbs) which recognize two 
purported TSP-l binding proteins, CD36 and the av 
integrin chain, or TSP-l-derived peptides CGRGDS 
and CSVTCG, alone or in combination with heparin, 
did not inhibit HDMEC adhesion to immobilized 
TSP-1. Furthermore, CSVTCG-ovalbumin COltju-
gates failed to support HDMEC adhesion. Although 
T hrombospondin- l (TSP-l) is a 450-kDa adhesive . glycoprotein which is a m ajor component of platelet a granules and m ay also be secreted by a va l;ety of cell types [1-3] . TSP-l is a hOl1lotrimer consisting of subunits with a m olecular weight of approximately 
180 kDa . Each subunit consists of multiple do m ains including an 
amino-te rminal heparin-binding domain , an adjacent region with 
bOJTlology to procoUagen, three types of repeated sequen~e motifs, 
and a carbol\.'y-terminal cell-binding domain (Fig 1). 
TSP-l exerts a variety of activities on endothelial cells ill lI illO and 
ill v itro. It has been identifleq as a tumor suppressor factor ill lI i llo and 
its anti-tumor effects are likely attributable to its potent anti-
angiogenic activity which has been character ized in the rabbi t 
corneal assay ill lI illo [4] . However, studies examining the effect of 
TSP-l on el1do ~helial cells ill Jlilro have yie lded diverse aJ~d often 
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RGD-containing peptides immobilized on plastic 
wells supported HI)MEC binding, they also induced 
cell spreading not characteristic of cell binding to 
TSP-l and binding was inhibited by free RGD pep-
tide. Two MoAbs against different domains of TSP-l 
(A4.1 and C6.1) failed to block HDMEC binding to 
TSP-l, but both MoAbs inhibited G361 human mela-
noma cell binding to TSP-l by 60%. Acid treatment of 
TSP-l alm.ost completely abrogated its ability to 
support HDMEC binding, while acid treatment in-
hibited G361 bindi~g by 50%. However, either anti-
body completely abrogated G-361 cell binding to 
acid-treated TSP-1. These data demonstrate that 
IJDMEC bind to immobilized TSP-l in an RGD- and 
CSVTCG-independent manner via an acid labile 
epitope(s) which is recognized via a recep~or or re-
ceptors distinct from CD36 or av{33 integrin recep-
tor. Key words: Tirrombosp01,diu-1Imicl'O llaSCII{arlell.dotlre-
liallmlgiogellesis. ] I,west Del'llrato{ 106:215-220, 1996 
contradictory results. III Jl ifro , TSP-l has been shown to both 
stimulate and inhibit endothelial cells proliferation , chemotaxis, 
and migra tion [4 - 7J. Additio nally, TSP-l plays an im po rtant ro le in 
homeostasis and thrombo-occlusive diseases , and its ro le in the 
developmen t of vaso-occlusive diseases has been suggested by its 
abiJi ty to m ediate abnormal red blo?d . cell binding to e ndothe lfal 
cells in SIckle cell anemla and m alana [8 -1 0]. "\. 
Each of these physiologic and pathologic activities of TSP- I is 
dependent upo n its interactio ns wi th endotheli al cells, primarily in 
the microvasculature. Previous studies that have examined the 
domain s of TSP-l important for cell hinding have dem onstrated 
that these important binding do m ains are very cell speciti c [11-16]. 
To understand the m echanism s of these diverse e ffects ofTSP-1 on 
the cutaneous vascula ture, we examined the binding of huma.n 
dermal Inicrovascular endothe lial cells (HDMEC) to imo bilized 
TSP-l. W e have found that human dermal microvascular endothe-
lial cells bind to immobilized TSP-1 via an RGD, CSVTCG, CD36, 
and av {33 integrin complex-independent mechanism and bind to 
immobilized TSP-l via m echanisms distinct fro l11 those previo usly 
described for other cell s. 
M ATEIUALS AND METHODS 
Isolation ofHDMEC HDMEC were isolated frO I11 human foreskins and 
passaged as described previously [1 7J. HDMEC "lc rc grown in a m edia 
consi sting of MC DB '13 1 (Gibco 13RL. Grand lsl:lI1d. NY) w ith 3D'Y. normal 
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Figure 1. Structure ofTSP-t. Schcm:ltic di"gralll of one subuni t of the 
thrombospond in- I mo lecule. indicating the amino-termina l heparin-bind-
ing domain. an adjacent region with homology to procollagcn, three types 
of repeated sequence rnotif~, and the carboxy-te rmina l ce ll-b inding domain. 
hUlIl an serum (Gibco BRL). 1 ng/ml ep idermal growth t'Jctor (Clonctics, 
San Diego. CA) .I /-J.g/m] hydrocorti sone (Sigma Chemica l Co., St. Louis, 
MO). penici llin . streptom ycin , amphote ricin B. and '1 X '10- 5 M dibutyryl 
cycl ic AMP (S igma) . Cell s were used between passage 3 and 6. 
Other Cells Human melanom;! cell lines C32 (ATCC C RL1585) and 
G361 (ATCC CRL 1424) were obta ined fro m American Type Cell C ul tu re 
(Rockvillc, MD) :lIld maintained in McCoy's 5a medium contai ning 'IO'ilu 
fetal bovine serum (Gibco BIU). 
Antibodies and Other Reagents Monoclonal antibody (MoAb) against 
CD36 (OKM5) was the generous gift of 0 1'. I'''tri cia Rao (R. \V . l ohmon 
PharmaccuticalR.esea rch Institu te. Rarita n. NJ). MoAb 10/5 and 13/10 
recognizing CD36 were gene ro usly provided by Dr. J olm McGregor 
(Institute Pascucr. L)'on. France). Hybridom"s producing MoAb 3F12 
against av in tegrin chain were the generollS gift of Dr. Eric Brown 
(Washington University. St. Louis, MO) [1 8] and were used as diluted 
asc ites. Rat MoAb 69-6-5, wh ich " Iso recognizes and blocks the fu nction of 
the c<v(33 incegrin complex. waS o btained fi'ol11 Illlnlunotech (Westbrooke. 
ME). Anti-TSP MoA b" A4. 1 11 3] ;/Ild C6.7 [1 9J were generously provided 
by Dr. W. Frazier (Washington University. St. Louis, MO). MoAb 4B4 
recognizing the (31 intcgrin chain was purchased from Coulter (Hialea h, 
FL). Po lyc/on,, ' anti-fibrinogen and anti-fibronectin antibodies were pur-
chased from Ca lbiochel11 . H eparin was purchased fi'ol11 Sigma. 
Isolation and Purification of TSP-l TSP-l was isolated frol11 human 
platelets as previo usl), described [1. 20). Fifteen units of fresh platelets from 
the Amel'ican Red Cross (Atlanta. GA) were washed three times in washing 
buffer (pH 7.6) containing 0.15 1'.1 NaCI, 0.05 M N-2-hydroxyethylpipera-
zine-N' -2-eth'lIl esulfonic acid and 10% anti-coagulant citrate dextrose 
(ACO) . They were then resuspended in 50 ml of 0.1 M N-2-hydroAl'cth-
ylpiperazinc-N'-2-ethanes ulfonic acid bufFer (pH 7.6) con tairung 0. 15 M 
NaCI, 5 mM dextrose, and 0 .3 mM C aC I" stimulated with \ U / ml 
th rombin with gentl e shaking at 37°C for 2- 5 min. The reaction was 
stopped by phcnylmeth ),lsulfony\ flu oride and benzamidine hydrochloride 
(Kodak. Rocheste r, NY) with fllla l concentrations of 0. 1 and 5 111M , 
respectively, and the aggregates were spun at 20.000g for 20 min. The 
supematallts were then frozen at - 70°C overnight. thawed, and respun at 
20.000.g for 1 h next morning. T he supernatan ts wcre then applied to " 
hcparin-Sepharose column, prewashcd "'~th 0.01 M Tris buffer (pH? .6) 
containing O.1S M NaC l and 0.3 mM CaC I?, and eluted with 0 .01 M Tris 
buffer (pH 7.6) containing 0.55 M NaCI and 0.3 111M CaCI, . Fractions were 
screened spectrophotomctri cally at O.D. 280 an d TSP-containing fractions 
were pooled . Contaminating fibronectin (Fn) was then removed by incu-
bating the poo led fi'actions twice with 1 1'111 of gelatin Scpharose (Sigm:.) for 
30 minutes with rotation at 4°C. T he supernatants were furthered purified 
by gel filtration on Sephacryl S-200 column. Fractions e lu ting in the void 
volume of the column demonstrated a single '180-kD" band On sodium 
dodccy l sulfate-po lyacrylamide gel electrophoresis (SOS-PAGE) lInder 
reducing condition and were further ide ntified by lInti-TSP-'1 MoAb by 
Western blot and cnzynlc-linkcd inl111unosorbcnt ass~ly. Contanlin,ltiol1 
with Fn and fi brinogen was determined to be less than 0.025 and 0.1% •• 
respecti vel y. 
Other Matrix Proteins Human plasma fi bronecti n and fibrinogen (each 
> 95'X. purity by SOS-PAGE) were purchased frOIll C hemicon (EI Segundo. 
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CAl, Vitronectin was purified (> 95% by SOS-PAGE) from human plasma 
by heparin sepharose chromatography as described [21] . 
Cell-Matrix Adhesion Assay Plates with 48 (Costa r) or 96 (Becton-
Dickinson) flat-bottom wells were coated with matrix prote ins or TSP-J-
de rived pep tides by overnight incubation in Hallks' balanced salt soluoon 
with divalent cations at 4°C . T he plates were then washed and blocked by 
incubation for t h with 2% bovine serum albumin (ICN Biochemical Inc.) 
in Hanks ' balanced salt solu tio n with diva lent cations. HOMEC were 
labeled overn.ight with SICr. A single T-?5 Hask containing 2.5 X 106 ce.Us 
was labe led with '100 f.LC i o( 51 Cr. and was sulllcient for 100 wel ls (plating 
density: 25.000 cells/well). HOMEC were removed from tissue eulnlfe 
plates with trypsi n/eth ylenediamine tetra acetic acid . washed, and resus-
pended in Ea rlc's ba lanced ,,,Jrs solucion (Gibco BRL) with divalent caoolll 
and 0.2% bovine serum albumin . Cell s were then allowed to reCover for 40 
min On ice, aliquottcd into individual wells or preineubated with MoAb or 
peptides for 45 min on icc. Al ternatively, coated wells were preill cubated 
with MoAb Or peptides for 1 h. After incubation , HOMEC were added to 
coated we lls. /11 some experiments. adhesion assays wel'e conducted ill the 
continuo us presence of MoAb or peptides, but in other experiments, treated 
HOMEC were washed prior to allowing them to adhere to coated \VeUs. 
After a 2-h in cuba tion, the plates were washed three times, adherent cells 
were lysed with 1% SOS. and associated rad ior.ctiv ity counted. 
In certa in experiments. TSP-l was acid treated after adsorption on to 
plates . TSP- '\ was coated on plastic well s as described above. Plates wcre 
blocked with bovine serum albumin and then treated for 30 min at room 
temperature with 100 ILl of phosphate-buffered sa line acid ified or alkalin-
ized with J M HC I or 1 M NaOH at a pH ranging fro m 1.0 to 9.0. Wells 
we re then extensive ly was hed and used as described above. 
Peptide Synthesis Pep tides were synthesized and purified :It the Emory 
Uni versity Microchemical Facili ty. Peptides were synthesized on an Applied 
Biosystel11 model 3804 solid phase peptide synthesizer. T he resultant 
peptides were cleaved alld purified by reversed phase high_pcrfom1>l1ce 
liquid chromatography (Waters) using acetonitritle. 0.1 % trifluoroacetic 
acid so lvent system . l'uri ty was tested with analytical high_performance 
liquid cltromatography. T he primacy structllre of the peptides were con-
firmed by amino acid composition on a Beckman model 6300 amino acid 
ana lyzer. and by sequencing with Applied Biosystems model 477A Se-
q uencer. All peptide preparations were tested for cytotoxicity on G361 cells 
by tryp" n blue exclusion and were not toxic at the concentrations employed 
in these experiments. 
Conpling of Pep tides to Ovalbumin Ovalbumin was activated by 
incubation for 30 min at room temperature with M-rml\eimidobenzoyl-N-
hydroxysuccinimide ester (Pierce) at a 1 :40 molar ratio in 0.05 M phosphate 
b ll trer. pH 8 .0, with 20% dimethylsulfox ide. Thl! activated ovalbumin was 
separated from free M-maleimidobenzoyl-N-hydroxysuccinimide ester by 
gel filtra tion on a G- 2S column (PD-l0 . Pharmacia), reconccntr"ted to 0.5 
ml using" ccntricon-30 (Amicon) and then incubated with t-2 mg peptide 
(molar f;ltiO I :20) for 3 h at room temperature. T he coupled product Wa.! 
separated from free peptide by ge l fi ltration. and the efficiency of coupling 
was checked by the loss of free cysteine residues utilizing Ellman 's reagent 
(Pierce). 
Electroblotting and Amino Acid Analysis Twenty micrograms of 
ovalbullliJI and ovalbumin-peptide cOI'!i ugates were rUIl respectively on an 
8% SDS gel using T ris-Glycine system and transferred to PolyvinyJidene 
difluoride membrane (ProBlottf11 from Applied Biosystems) for 2 h at 
constant current of 0.8 mA . T he prote in saniples on ProBlott we re detected 
with Coomassie Brilliant l3Iue stain.ing, destained with 50% methanol in 
distilled water, and .~ubseq ll cntly sequenced in microchemical f.1cility at 
Emory University. 
RESULTS 
HDMEC Bind to but Do Not Spread on Thrombospondin-l 
HDMEC b o und to TSP-l in a con centration- and diva lent cation-
d ependent fas hion. Binding was observed at coating con cen trations 
as low as 5 p.g/ml and m aximal binding was observed at concen-
trations of 25 p.g/ml or greater (Fig 2). Average binding of 
HDMEC to surfaces coated with 2S p.g/ml of TSP-l was 52 :!: 
7.2% (n = 12). T his was comparable to average maxima l bi.nding to 
vltron ectin (49 .2 ::': 1.7%, n = 3), but substantially less th an binding 
to fibron ectin (74.1 ::': 9.5%, 11. = 4). J-lDMEC plate d on TSP- l 
coated plastic wells bound but did n ot spread (Fig 3a). Treatment 
of TSP-l with re ducing agent failed to induce HDMEC spreading 
as prev iously described for bovine aorti c end othelial cell s [20] . In 
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F igure 2. Binding of HDMEC to TSP-l is concentration dcpcn-
dent. Signifi cant binding was observed a t coating concen tratio n as low as 
5 Mg/ml and max imal binding was obse rved at concentration of 25 Mg/ ml 
or greater. Data shown represen ts the results of one of fo ur expe riments 
examining concentration depende nce. Data points shown are fi'om a single 
experiment; error bn"" SO (n = 3). 
contrast, HDMEC both bOlUld to and spread on .imlllobilized 
fibronectin. (Fig 3b) or vitronectin (data not shown) . 
Previous work has also suggested that polY'Ulionic compounds 
such as heparin or fu coidaJ1 may inhibi t cell binding to TSP-l 
[1 1,12,19]. W e therefore examin ed the e ffect o f heparin and 
F igure 3. HDMEC bind to but do not spread 011 TSP- l. HDMEC 
p lated o n TSP-l (25 Mg/ml) (n) ,md fibron ectin (10 Mg/ ml) (I,) coated 
p lasti c w e \J s and incuba ted for 2 h . As has been described w ith other cell 
types, HDMEC bind to but not spread o n immobili zed TSP-l . In contrast, 
HDMEC both bind to and spread on immobilized ftbron cctin. Sca le bars, 
23 MII1. 
fucoidan on the binding of HDMEC to immo bilized TSP- l (25 
JLg/ m l) . Onl y very modest inhibition ofH DMEC binding to TSP-1 
was induced by fucoidan (control 47 :±: 4%, fu coidan 0.5 mgl ml 29 
::!:: 7%, 38')-(, inhibition, n = 3) but not by heparin (control binding 
55 ::!:: 9%, heparin 1 mg/ ml 51 ::!:: 14%, 9% in hibition, 11 = 8). 
Heparin and fu coidan w ere more effective as an inhibi tor of the 
binding ofC32 or G361 melanoma cells to TSP-l (25 JLg/ ml). T he 
binding of C32 cells to TSP-l was inh.ibited by heparin by 53% 
(control 58 ::!:: 6%, heparin 1 m g/ml 27 ::!:: 5%, n = 4) and the 
binding of G361 cells was inhibited by 64% (control 67 ::!:: 1%, 
fu coidan 0 .5 mg/ ml 23 ::!:: 7%, n = 2). T hese data suggested that 
HDMEC recognize TSP-l via m echanisms distinct from what has 
been previously described for other cell types . 
CD36 and Il'V Integtin Complexes on HDMEC Do Not Bind 
to Itutuobilized TSP-l Previous studies hav e sugges ted that 
two cell surfa ce receptors, CD36 and av{33 integrin complex, play 
an important role in endothelial cell binding to TSP-l [8,11-14]. 
Sin ce HDMEC express both CD36- and av- containing integrul 
complexes (a v{33 and av(3 5) i/l ,,;(ro and ;/1 /1; //0 [22,23], we utilized 
functiona l blocking MoA bs recogniz ing these receptors in assays 
examinulg HDMEC binding to immobilized TSP-l. MoAbs against 
CD36 or av alone did not affect HDMEC binding to TSP-l (Fig 
4A ). Since bo th CD36 and av{33 compl ex on HDMEC could 
mediate binding to TSP- l , it was possible that .ulhibition by on]y 
one an tibody would not affect FID MEC bUlding. However, com-
bination of antibodies with or \¥i thout heparin (data not shown) 
also fa iled to affect cell adhesion to TSP- 1 (Fig 4A) , and these 
results were found consistent over a wide ran ge of antibody 
concentrations (OKM5 1-100 JLg/ ml; 3F12 ascites diluted 1:10-1 : 
100). 
One possib le explanation for our results was that o ur an tibodies 
were not functionally active. However, both MoAb OKM5 and 
3F12 are functionally active. Previous studies w ith MoAb OKM5 
using HDMEC have shown that it binds to HDMEC and inhibits 
C D 36-dependent adhesive fun ctions [8,21]. MoAb 3F12 inhibits 
HDMEC binding to vitronectin (Fig 4B) . Additionally, con sistent 
results were obtained by using other M oAbs recognizing CD36 
(10 15 and 13/10) and av (MoAb 69-6-5) . These data clearly 
suggested that other adhesion receptors other than C D3 6 and av{33 
on HDMEC ar e critical for HDMEC adhesion to immobilized 
TSP-1. 
CSVTCG Peptide Does Not Support HDMEC Binding 
Since we were not able to demonstrate a fun ctional role of CD36 
and the av{33 ultegrin chain in HDMEC adh erence to immobilized 
TSP-l by using specific blocking antibodies, we utilized soluble 
peptides fi'om TSP- l and peptides coupled to ovalbumin as tools to 
examine regions ofTSP-l critical for HDMEC binding. Previously 
studies examining the bUlding of endothelial cells to T SP-l have 
suggested that the VTCG sequence within the type 1 repeats is 
important in binding to CD36 and the RGD sequen ce in the last 
type 3 repeats is critical to bUldulg to the av{33 receptor. However, 
we found that soluble peptides containing eith er ' VTCG or RGD, 
alone or in combination with hep arin , did not ulhibit HDMEC 
bindulg to TSP- l (Fig 4Q. T hese pcptides were fun ctionally active 
since free RGD peptide inhibited HDMEC binding to vitronection 
(Fig 4B). CSVTCG peptide inhibi ts bindin g ofTSP-l opsonized or 
malaria infected red blood cells to HDMEC 1110nolayers under flow 
conditions (Wick T, pe rsonal communication). 
Pep tides w ere then coupled to ovalbumin and the peptide-
ovalbumin conjugates were immobilized on plastic wells to exam-
ine their ability to support HDMEC binding. HDMEC both bouud 
and spread on immobilized RGD-ovalbumin conjugates. However, 
it is not likely that HDMEC binding to TSP-l was R GD m ediated 
since HDM EC did not spread on TSP- l , w hil e R.GD-mediated 
adhesion was always accompanied by spreading. Additionally, the 
binding of HDMEC to R GD-ovalbumin was inhibited by free 
R GD peptide , whi le the bindulg to TSP-1 was not affected . 
T he VTCG repeats ofTSP-1 have been shown to act as a binding 
site for CD36 on selected cells [1 2,24]. We have previously shown 
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Figure 5. MoAb against TSP-l inhibit G-361 but not HJ)MEC 
binding to TSP-l. MoA bs A4 .1 and C6.7 (both at 50 fLg/ ml) against 
TSP-l. alone or in conjunction did not block HDMEC bindiJlg to TSP-l , 
while the binding ofG361 cell s to TSP-l was inhibited. Data poillts shown 
:0 B are from a single experiment; cn-or '",rs. SO (n = 3). 
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Figure 4. Neither anti-CD36 or av MoAbs nor CSVTCG or RGD 
peptides inhibit HDMEC binding to TSP-l. MoAb recognizing CD36 
(OKM5. 50 fLg/ml) or av{:l3 intcgrin complex (3F12. "scites 1:10; 69-6-5, 
'100 fLg/ll1l) and hepa rin (1 mg/l11l) d id not inhibit I-TDMEC binding to 
TSP-l (25 fLg/Il1I). T he combina tion of MoAbs OK.M5. 3F12, and 69-6-5 
with heparin also fai led to affect the binding ofHDMEC to TSP-l (A). Both 
R.GD peptide (50 fLg/ ml) and MoAb 3F12 (ascites diluted 1:10) . but not 
R.GE peptide (50 /J.g/ml) and MoAb 4134 (50 fLg/ ml) inhibited HDMEC 
binding to vitroncctin (30 fLg/ml) (B). Similar to antibody blockade studies. 
pretreatment of HDMEC with CSVTCG (50 /J.g/ml), CGR.GDS (50 
/1.g/ml) peptides. or of TSP-1 with heparin (1 mg/ ml) alone or in 
combination did not inhibi t HDMEC adhesion to TSP- l (C). Data points 
shown arc from a single experiment; em>r bnrs, SD (11 = 3). 
that HDMEC express CD36 and that it may function as an adhesion 
receptor for malaria infected red cells [22], presllmably via its 
interaction with VTCG repeats. However, HDMEC did not bind to 
immobilized CSVTCG peptide or its ovalbumin conjugates (data 
not shown). T he coup lin g of pep tides was done usi ng MES, whi ch 
li nks peptides via free amino g roups on lysine. In order to deter-
mine whether the CS VTCG peptides were actually co upled to 
Qvalbumin. we determined the amino acid sequence of the amino 
terminus of CSVTCG-ovalbumin conjugates and found that it 
matched that of the CSVTCG peptide (data not shown) . Therefore, 
the lack of binding to the peptide-ovalbumin conjugate was not due 
to the lack of available CSVTCG peptide. These data suggested 
that HDMEC binding to immobilized TSP-l was independent of 
RGD/CSVTCG domains on TSP-l , and that the adherence to 
immobilized TSP-1 was mediated via mechanisms distinct fr0111 
those utilized to bind to soluble TSP-1. 
Anti-TSP-l MoAb Do Not Inhibit HDMEC Binding to 
TSP-1 MoAbs A4.1 and C6.7 have been previously charactetized 
for theiT ability to inhibit cell binding to TSP-1. MoAb 4.1 has been 
mapped to the central stalk region of TSP-1, while MoAb C6.7 
binds to the carboJ<..'Y-terminal domain (19). Surprisingly, neither 
antibody, alone or in com bination affected binding of HDMEC to 
TSP-1 (Fig 5). However, both antibodies were functionally active 
since they inhibited binding of G361 cells to TSP-l by 60%. 
HDMEC Bind to Acid Labile Domains of TSP-1 Acid 
treatment ofTSP-1 resulted in almost· complete loss of its adhesive 
activity for HDMEC (Fig 6) . However, acid treatment of TSP-t 
only partially inhibited G361 binding (50%). HDMEC binding to 
vitronectin and fibronectin was not affected by acid treatment. Acid 
treatment did not affect the recognition of TSP-1 by MoAb 4.1 or 
C6. 7, demonstrating that the TSP-1 was still adherent to wells and 
that the domains recognized by the two M oAbs were not acid 
labil e. The binding of G361 cells to TSP-1 could be completely 
ablated by pretreating TSP-l with acid followed by preincubation 
with MoAb A4.1 or C6.7 (Fig 6) . These data suggested tbat 
HDMEC binding to TSP-l was almost compl etely dependent upon 
recognition of acid labile domains which are distinct from those 
domains previously defin ed with blocking MoAbs. 
DISCUSSION 
T he inte raction of TSP-1 with endothelial cells, particula.rly those 
of the microvasculature, appears to be critically important in the 
control of angiogenesis associated with wound healing and tumor 
growth . TSP-l inhibits growth f~l ctor induced proliferation of 
endoth elial cells, and also acts as an inhibitor of;/I IJ;11O angiogenesis. 
This activ ity is likely to be central to its activ ity as a tumor 
suppressor factor. Recent studies have implicated the tumor sup-
pressor activ ity of the p53 gene may actuall y be mediated vi ,1 TSP-l 
effects on vascular growth [25]. Additionally, TSP-1 also appears to 
play an important role in mediating erythrocyte- endothelial cell 
interactions in malaria and sickle cell diseases [8.9]. The m echa-
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Figure 6. HDMEC bind to an acid labile domain of TSP-l. Acid 
tre atme nt ofTSP-l resulted in almost complete loss of its adhes ive activity 
for HDMEC binding; however, th e binding ofG361 cells was only partia lly 
inhib ited, and this binding could be completely ablated by pretreating 
TSP-l with acid followed by preincubating TSP-l with MoAb A4. 1 or C6.7 
(50 J.Lg / ml). Data points shown arc fro lll a single experime n t; ermrl," r.--, SD 
(n "" 3) . 
nisms w hich m ediate these effects are not welJ detined . It is 
probabl e that TSP-1 directly interacts with microvascular endothe-
lia] ce lls. However, the m echani sms that m ed iate the in te raction of 
TSP-l with human endo the lial cells , particu larly those derived 
fro m the microvasculature, are not entirely clear. 
T he study of adhesive fun ctions of TSP-l is complicated by the 
presence of mul tiple adhesive do m ains and cell surface receptors 
w hich may in te ract in a cell specific manner. TSP-1 has at least five 
characterized adhesive domains. T he am inoterminus of TSP-1 
con ta ins a heparin binding site which may bind to an integral 
membrane hepa rin sulfa te proteoglyca n on cells [2,3]. Adj :lcen t to 
this heparin binding site is a region with hom o logy to procoll agen 
w hich m ay be adhesive for HDMEC' ,md has also been shown to 
be an ti-angiogenic ill /)iI/O [4]. T he central sta.lk of TSP-l contains 
properidin-like repeats w hich also bind heparin and may support 
cell adhesion. T his portion con tains CSVTCG repeats which have 
been purported to bind to CD36 as well as a distinct 60-kDa 
receptor on carcinoma cells [15,24]. In addition, a sequence 
adj acen t to th e CSVTCG has been reported to suppo rt m elan oma 
cell binding in a CS VTCG-independent manner l26] . Adjacent to 
the c3rboxyterminus of TSP-l are 3 series of calcium binding 
repeats which contain an R GD sequence w hich h 3S been reported 
to interact with th e O'v{33 integrin complex [1 4]. Fina.lly, the 
ca.rboxyterminu s of TSP-l supports ce lls binding via at least two 
distinct receptors which h ave been partially characterized [1 6,27] . 
Tn o rder to characterize the m echanism s m ediating HDMEC bind-
ing to immobilized TSP-l , we utilized a variety of reagents 
targeting eithe r cell surface receptors of HDMEC o r binding 
dom ain s of TSP-l to define the importance of specific cel.l surface 
receptors or TSP-l do m ains. 
TSP-1 contains two heparin-bindin g domains, located in the 
amino- terminal globular domain and the central stalk region [3,26], 
w hich may mediate cell adhesion by binding to celJ surf.1ce 
proteoglycans. Previous studies have shown that certain polysac-
charides such as heparin can inhibit binding of selected cells to 
immobilized TSP-l and binding of bovine endothelial cells to 
TSP-1 in fluid phase [11 ,1 2,28]. However, the effect of heparin and 
related compo unds on the adhesio n of human microvascular endo-
thelial cells to immobilized TSP-l has not been previously exam-
I Chen ZS, WS Frazier. TJ Lawley, lU\ Swerli ck : C haracteriza tion of 
h uman d ermal e ndothelial cell in teraction s w ith th rombospondin-l. ] Ill lleS I 
Dcrll/alol 102 :6393, 1994 (abst.) 
ined. In o ur m odel , both heparin and fuco idan were effective at 
inhibiting C32 or G361 cell binding to TSP at equ iva lent concen-
trations. However, heparin had li ttle e ffect on HDMEC binding to 
immobilized TSP-l. In addition , altho ugh fucoidan ca used a some-
w ha t greater inhibiti o n of HDMEC binding, fu coidan was much 
less effective at inhibiting HDMEC binding than G361 binding. 
T hese data are consisten t with previolls studies of bovine endothe-
lial cells [5] and suggested that, a.Ithough other cells may utilize 
heparin binding domain s of TSP-l for adhesion , HDMEC utilize 
different adhesion pathways to bind to immo bilized TSP-l. 
Multiple cell surface receptors have been implicated in cell 
binding to TSP-l. Som e of these receptors arc w ell characterized 
w hile a number ha ve not been characterized by either antibodies or 
eDNA probes. T he role of two well characterized receptors , the 
av{33 complex and CD36, were examin ed utili zing b locking 
MoAbs in adhesion assays. T he related {33 integrins (Xv{33 , w hich is 
expressed on a variety of nucl eated cell s, and the platelet-specific 
a Ilb{33 (GPllb / lla) complex have both been impli cated in cell 
binding to TSP-l [1 4,29). In order to determine w hether these 
specific cell surface receptors mediate HDMEC binding to immo-
bilized TSP-l, we ut ilized blocking MoAbs recognizin g CD36 and 
the av{33 intcgrin complex (3F12) in cel.l adhesion assays . Neither 
antibody alone 0 1' ill com bination affected HDMEC bindiJlg to 
TSP-l. T his was surprising since we have previollsly shown that 
both of these antibodies w ere effective at inhibi ting TSP- l-l11edi-
ated erytlu-ocyte adhesion to HDMEC [8]. One possible explana-
tion is that HDMEC recognize immobilized TSP-l via different 
m echanisms used to recognize TSP-l in fluid phase. Previous 
studies have provided evidence supporting this possibili ty [30] , and 
recognition of other plasma proteins such as fib l'inogen, von 
Wille brand factor , o r vitronectin have been shown to be m ediated 
via distin ct mech anism s depending upon w heth er the adhesion 
protein wasiJ1 fluid or solid phase [31,32]. 
T he central portion of TSP- l contains type r re peats w hich 
contain the CSVTCG sequence w hich bas been shown to m ediqte 
adhesion of certa in cell types . At leas t two distin ct receptors have 
been purported to m ediate this binding. CD36 is an 88-kDa cell 
surface protein w hich has been found in a variety of cell types, 
including microvascular endothelial cell s [1 3,22]. It h as also been 
described as platelet protein GPIV. CD36 has been implicated as a 
TSP-l receptor via biJ1ding to the VTCG sequence within type 1 
repeats of TSP-l [24] , w hile a second 60-kDa receptor o n carci-
noma cells has also been implicated [15] . Because CD36 did not 
appear to play an important role in HDMEC binding to immobi-
lized TSP-l , it is w11ikely that the domains of TSP-l w hich are 
recognized by this receptor are important for HDMEC binding. 
However, since an addi tional receptor distinct £]-OIn CD36 h as also 
been implicated as a receptor for CSVTCG, soluble CSVTCG 
peptide was utilized in blocking studies. Similar to our antibody 
blockade studies, free CSVTCG peptide and the synthetic peptide-
ovalbumin conju gates did not inhibit HDMEC binding to TSP-l. 
Additionally, CSVTCG peptide in combinatio n witl1 RGD peptide 
and heparin fa iled to affect HDMEC binding to TSP- l. 
Free CSVTCG or its ovalbumin conjugates fa iled to support 
HDMEC binding. Altho ugh HDMEC were capable of utilizing 
RGD containing p 'i!ptide fu r adherence, the binding was accompa-
nied by spreading and could be blocked by free RGD peptide, 
f1l1dings in contrast to HDMEC binding to TSP- 1. These data 
provide strong evidence that although HDMEC bind to immobi-
lized TSP-l, the binding is independent of CD36 or O'v{33 recepto rs 
on HDMEC and the R GD or VTCG domains o n TSP-1 . 
Previous studies have suggested that certain large vessel endo-
theli al cells m ay bind to immobilized TSP- l via an RGD-depen-
dent mechanism [5,14,20]. It is clear that recognition and be havior 
of cells o n TSP- l is very cell dependen t. T he bindin g ofHDMEC 
or umbilical vein endothelial cells to TSP-l was not associated with 
cell spreading [1 4] , bu t variabl e results have been reported w.ith 
bovin e aortic endothelial cells [5,20 ,32] . W h.il e a single report 
dem o nstrated R GD-dependent binding of human endothelial cell s 
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fro m umbilica l vein [14], o ur data suggest that HDMEC do not use 
this mechani sm to bind to immobilized TSP- l. 
Additionally, two other receptor candidates have been partially 
characte ri zed . Two receptors appear to recognize the carbo~.'yter­
minus of TSP-l and both are inhibi ted by MoAb 6.7. T he first, 
described by Yabkow tiz and Dixit [16] o n a carcinoma cell lin e, 
was identified by affinity chromatography and consisted of an 80-
and 105-kDa complex. T he second is recently identified 52-kD 
pro tein on ~562 cells and binds to laminin-like repeats in th e 
carboxy terminus of TSP-l [27). T he ro le of these receptors in 
HDMEC binding to TSP-l has not been directl y addressed . 
Interaction of ca rcinoma cells with TSP-l via the 80/105-kDa 
complex was inhibited by MoAb 6.7 which is directed against the 
carboxy terminus ofTSP-1. In contrast, MoAb 6.7 had no effect 011 
HDMEC binding to TSP-l , making invo lvement of the 80/105-
kDa receptor unlikely. Similarly, the in volvement of the 52-kDa 
receptor w hich also interacts w ith the carboxytermius of TSP-l is 
also unlikely. 
Previous studies w ith MoAbs recogniz in g specific domains of 
TSP-l have demonstrated that two MoAbs A4.1 and C6.7, can 
inhibit G361 cell binding and studies in our laboratory support this 
observation, altho ugh the inhibitio n noted with e ither MoAb was 
o nly about 60°/r,. Surprisingly, neither of th ese antibodies affected 
HDMEC binding, providing further evidence that HDMEC utilize 
unique sites o n TSP-l for binding. However, th e binding of 
HDMEC was alm ost completely ablated by pretreatment of TSP,.l 
with acid, while the binding of G361 cells was only partiall y 
inhibited by acid treaqnen t: The remaining portio n of G361 
binding was completely ablated by MoAb A4.1 o r C6.7, indicating 
that these M oA bs recogni~,ed sites distinctive from the acid labile 
site(s) . These data furth er support o ur hypothesis that HDMEC 
utilize exclusively an ac id labile site(s) in binding to immobilized 
TSP-l, and do not utilize epi topes defin ed by MoAb A4.1 or C6 .7 . 
Endothelial cell interactions with TSP-l are cen tral to the 
regul ation of angiogenesis and thrombosis. Our studies provide 
evidence that human dermal microvascular endothelial cells utilize 
unique sites on TSP-l fo r adherence. Further characterization of 
these sites and the recepto rs which recognize them is importan t to 
im prove our understanding of TSP-l endothelial ce ll interactions. 
T"is work was slippOlted by II Natiollal [lI sli/liles "J H enll" G rallls R29 AR4 1710 
alld R01 AR 36632, a",1 II)' a Dl'fJllalology FO Hl,dalioli Fell" ws"il' A ward (Dr. 
C"ett). 
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